EFFECTS OF CYP2C19 AND P2Y12 GENE POLYMORPHISMS ON CLINICAL RESULTS OF PATIENTS USING CLOPIDOGREL AFTER ACUTE ISCHEMIC CEREBROVASCULAR DISEASE

Basit Öğe Kaydı
dc.authoridSılan, Coşkun/0000-0002-8352-6571
dc.contributor.authorSen, H. M.
dc.contributor.authorSılan, Fatma
dc.contributor.authorSılan, Coşkun
dc.contributor.authorDegirmenci, Y.
dc.contributor.authorKamaran, Ozisik H., I
dc.date.accessioned2025-01-27T20:22:55Z
dc.date.available2025-01-27T20:22:55Z
dc.date.issued2014
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractThe CY2C19 and P2Y12 gene polymorphisms are responsible for resistance to clopidogrel, known as drug unresponsiveness. In this study we researched the effect of gene polymorphism on clinical results of patients who began clopidogrel therapy after acute ischemic cerebrovascular disease. The study included 51 patients. The patient group included patients who had begun prophylactic clopidogrel due to acute ischemic cerebrovascular disease in the last 2 years. All patients were monitored by the Neurology Outpatient Clinic at Canakkale Onsekiz Mart University Research Hospital, Canakkale, Turkey, and only those monitored for at least 1 year were included in the study. When the *1, *2 and *3 alleles of the CYP2C19 gene polymorphism were evaluated, two patients were homozygotes for *2/*2, 13 patients were heterozygous for *1/*2 and 36 patients were homozygotes for the wild type *1/*1. No patient had the *3 allele. Three heterozygous patients, one for *2/*2 and two for *1/*2, stopped clopidogrel therapy due to repeated strokes and began taking warfarin. When evaluating P2Y12 52 (G>T) and 34 (C>T) polymorphisms, all alleles were of the wild type. The CYP2C19 and P2Y12 gene polymorphisms may cause recurring strokes linked to insufficient response to treatment of ischemic cerebrovascular disease. In our patient group, three patients suffered repeated strokes and these patients had the CYP2C19*2 gene polymorphism. As a result, before medication use, genetic testing is important for human life, quality of life and economic burden.
dc.description.sponsorshipDepartment of Scientific Research Projects Commission, Canakkale Onsekiz Mart University, Canakkale, Turkey
dc.description.sponsorshipThe present study was supported by the Department of Scientific Research Projects Commission, Canakkale Onsekiz Mart University, Canakkale, Turkey. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.
dc.identifier.doi10.2478/bjmg-2014-0072
dc.identifier.endpage41
dc.identifier.issn1311-0160
dc.identifier.issue2
dc.identifier.pmid25937796
dc.identifier.scopus2-s2.0-84928478863
dc.identifier.scopusqualityQ4
dc.identifier.startpage37
dc.identifier.urihttps://doi.org/10.2478/bjmg-2014-0072
dc.identifier.urihttps://hdl.handle.net/20.500.12428/22070
dc.identifier.volume17
dc.identifier.wosWOS:000352978700004
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMacedonian Acad Sciences Arts
dc.relation.ispartofBalkan Journal of Medical Genetics
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectIschemic cerebrovascular disease (ICVD)
dc.subjectclopidogrel
dc.subjectCYP2C19 and P2Y12 gene polymorphisms
dc.titleEFFECTS OF CYP2C19 AND P2Y12 GENE POLYMORPHISMS ON CLINICAL RESULTS OF PATIENTS USING CLOPIDOGREL AFTER ACUTE ISCHEMIC CEREBROVASCULAR DISEASE
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu